Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.
- Author:
Jihye PARK
1
;
Jae Hee CHEON
Author Information
- Publication Type:Review
- Keywords: Behcet syndrome; Intestinal Behcet's disease; Anti-tumor necrosis factor alpha; Infliximab; Adalimumab
- MeSH: Adalimumab; Behcet Syndrome; Certolizumab Pegol; Etanercept; Humans; Inflammatory Bowel Diseases; Infliximab; Necrosis*
- From:Gut and Liver 2018;12(6):623-632
- CountryRepublic of Korea
- Language:English
- Abstract: Intestinal Behçet's disease is a rare, immune-mediated chronic intestinal inflammatory disease; therefore, clinical trials to optimize the management and treatment of patients are scarce. Moreover, intestinal Behçet's disease is difficult to treat and often requires surgery because of the failure of conventional medical treatment. Administration of anti-tumor necrosis factor–α, a potential therapeutic strategy, is currently under active clinical investigation, and evidence of its effectiveness for both intestinal Behçet's disease and inflammatory bowel diseases has been accumulating. Here, we review updated data on current experiences and outcomes after the administration of anti-tumor necrosis factor–α for the treatment of intestinal Behçet's disease. In addition to infliximab and adalimumab, which are the most commonly used agents, we describe agents such as golimumab, etanercept, and certolizumab pegol, which have recently been shown to be effective in refractory intestinal Behçet's disease. This review also discusses safety issues associated with anti-tumor necrosis factor–α, including vulnerability to infections and malignancy.
